Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 14/20 | 0.54 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6411650 | 0.89 | SIRT2 (0.51) | MEN1KMT2ASIRT2SIRT1 | |
| SCHEMBL6504152 | 0.83 | CCR8 (0.52) | CCR8MGLLKCNH2MEN1KMT2A | |
| SCHEMBL1034082 | 0.77 | SPHK1 (0.43) | KMT2ASIRT1 | |
| SCHEMBL14738426 | 0.77 | SPHK1 (0.43) | KMT2ASIRT1 | |
| SCHEMBL3173400 | 0.77 | SPHK1 (0.45) | MGLL | |
| SCHEMBL3172552 | 0.75 | CD274 (0.38) | KCNH2MEN1KMT2A | |
| SCHEMBL6505185 | 0.74 | CCR8 (0.45) | CCR8MGLLKCNH2MEN1KMT2A | |
| SCHEMBL3135777 | 0.73 | CCR8 (0.61) | CCR8MGLLKCNH2MEN1KMT2A | |
| SCHEMBL1845087 | 0.73 | CCR8 (0.62) | CCR8MGLLKCNH2MEN1KMT2A | |
| SCHEMBL6504157 | 0.73 | CCR8 (0.66) | CCR8MGLLKCNH2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | CCR8 1/4885MGLL 997/4885KCNH2 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.